Mono-N-terminal poly(ethylene glycol)-protein conjugates.

[1]  S. Kohno,et al.  Effects of Renal Function on Pharmacokinetics of Recombinant Human Granulocyte Colony-Stimulating Factor in Lung Cancer Patients , 2001, Antimicrobial Agents and Chemotherapy.

[2]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[3]  I. Pastan,et al.  Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Crawford,et al.  Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Takahara,et al.  Transglutaminase-mediated dual and site-specific incorporation of poly(ethylene glycol) derivatives into a chimeric interleukin-2. , 2000, Bioconjugate chemistry.

[6]  L. Harker,et al.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers , 2000 .

[7]  C. Begley,et al.  Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans , 2000, Growth factors.

[8]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[9]  M. Whitlow,et al.  Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. , 1999, Bioconjugate chemistry.

[10]  Mariangela Spitali,et al.  Therapeutic antibody fragments with prolonged in vivo half-lives , 1999, Nature Biotechnology.

[11]  D. Brems,et al.  PEGylation Prevents the N-Terminal Degradation of Megakaryocyte Growth and Development Factor , 1998, Pharmaceutical Research.

[12]  J. D. Yang,et al.  Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. , 1998, Protein engineering.

[13]  T. Dexter,et al.  Filgrastim (r-metHuG-CSF) in clinical practice , 1998 .

[14]  Samuel Zalipsky,et al.  Poly(ethylene glycol): Chemistry and Biological Applications , 1997 .

[15]  R. Paxton,et al.  Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling* , 1997, The Journal of Biological Chemistry.

[16]  J. Gabrilove,et al.  Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.

[17]  D. Brems,et al.  Characterization and Stability of N-terminally PEGylated rhG-CSF , 1996, Pharmaceutical Research.

[18]  R. Offord,et al.  Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. , 1996, Bioconjugate chemistry.

[19]  D. Lacey,et al.  Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. , 1995, Blood.

[20]  D. S. Hage,et al.  Studies on the rate and control of antibody oxidation by periodate. , 1995, Analytical biochemistry.

[21]  H. Lu,et al.  Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. , 1995, Blood.

[22]  A. Iwamatsu,et al.  Purification and characterization of thrombopoietin. , 1995, Journal of biochemistry.

[23]  I. N. Topchieva,et al.  Synthesis and physicochemical properties of protein conjugates with water-soluble poly(alkylene oxides). , 1995, Bioconjugate chemistry.

[24]  G. Griffiths,et al.  Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments. , 1995, Journal of immunology.

[25]  S. Zalipsky.  Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. , 1995, Bioconjugate chemistry.

[26]  J. Burnier,et al.  Subtiligase: a tool for semisynthesis of proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Beeler,et al.  The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. C. Hu,et al.  Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpI , 1994, Cell.

[29]  Scott R. Presnell,et al.  Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo , 1994, Nature.

[30]  D. Goeddel,et al.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand , 1994, Nature.

[31]  I. Pastan,et al.  Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. , 1994, The Journal of biological chemistry.

[32]  S. Shak,et al.  Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation. , 1994, Bioconjugate chemistry.

[33]  I. Pastan,et al.  Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. , 1993, Cancer research.

[34]  A. Irvine,et al.  Polyethylene glycol (PEG) modification of granulocyte‐macrophage colony stimulating factor (GM‐CSF) enhances neutrophil priming activity but not colony stimulating activity , 1992, British journal of haematology.

[35]  A. Irvine,et al.  Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. , 1992, Experimental hematology.

[36]  Shan S. Wong,et al.  Chemistry of Protein Conjugation and Cross Linking , 1991 .

[37]  M. Hershfield,et al.  Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Tanaka,et al.  Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. , 1991, Cancer research.

[39]  M. Léonard,et al.  Improvement of oxygen-carrying properties of human hemoglobin by chemical modification with a benzene hexacarboxylate-monosubstituted polyoxyethylene , 1991, Journal of protein chemistry.

[40]  H. Tanaka,et al.  PHARMACOKINETICS OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (KRN8601) IN THE RAT , 1991 .

[41]  R. Pool.  "Hairy enzymes" stay in the blood. , 1990, Science.

[42]  R. Goodson,et al.  Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site , 1990, Bio/Technology.

[43]  R. Wetzel,et al.  A general method for highly selective cross-linking of unprotected polypeptides via pH-controlled modification of N-terminal alpha-amino groups. , 1990, Bioconjugate chemistry.

[44]  J. M. Harris,et al.  LABORATORY SYNTHESIS OF POLYETHYLENE GLYCOL DERIVATIVES , 1985 .

[45]  G. E. Means.  Reductive alkylation of proteins , 1984, Analytical biochemistry.

[46]  D. Penington,et al.  Regulation of Platelet Production: ‘Hypersplenism’ in the Experimental Animal , 1967, British journal of haematology.

[47]  E. Kelemen,et al.  Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. , 1958, Acta haematologica.

[48]  G. Senaldi,et al.  The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice. , 1999, Experimental hematology.

[49]  W. Sheridan,et al.  Thrombopoiesis and Thrombopoietins , 1997, Humana Press.

[50]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry , 1992 .

[51]  M. Wilchek,et al.  Labeling glycoconjugates with hydrazide reagents. , 1987, Methods in enzymology.